Inhibitors of macropinocytosis in prevention and treatment of disease

Abstract

Described herein are pharmaceutical compositions capable of inhibiting vesicle formation and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat pathogenic infections.

1 . A pharmaceutical composition capable of inhibiting macropinosomal vesicle formation and having the general formula (I) or a pharmaceutically acceptable derivative thereof: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The pharmaceutical composition of  claim 1 , further comprising therapeutically effective amount of a pharmaceutical composition having the general formula (I), and a pharmaceutically acceptable carrier. 
     
     
         3 . A method for treating or preventing a viral infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition having the general formula (I). 
     
     
         4 . The method of  claim 3 , wherein the viral infection is an Ebolavirus infection. 
     
     
         5 . The method of  claim 3 , wherein the viral infection is a Marburgvirus infection. 
     
     
         6 . A method for treating or preventing a bacterial infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition having the general formula (I). 
     
     
         7 . A method for treating or preventing a protozoal infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition having the general formula (I). 
     
     
         8 . A pharmaceutical composition capable of inhibiting macropinosomal vesicle formation and having the general formula (II) or a pharmaceutically acceptable derivative thereof: 
       
         
           
           
               
               
           
         
       
     
     
         9 . The pharmaceutical composition of  claim 8 , further comprising therapeutically effective amount of a pharmaceutical composition having the general formula (II), and a pharmaceutically acceptable carrier. 
     
     
         10 . A method for treating or preventing a viral infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition having the general formula (II). 
     
     
         11 . The method of  claim 10 , wherein the viral infection is an Ebola virus infection. 
     
     
         12 . The method of  claim 10 , wherein the viral infection is a Marburg virus infection. 
     
     
         13 . A method for treating or preventing an intracellular bacterial infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition having the general formula (II). 
     
     
         14 . A method for treating or preventing a protozoal infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition having the general formula (II).